This was supported by a clinical study of newly diagnosed glioblastoma patients that reported significantly attenuated CD8 T cell infiltration in samples from long-survival patients (>403days) relative to that in samples from short-survival patients (<95days; Yang et al., 2010). This evidence concerns the gene CD8A and glioblastoma.